Flavoxate Hydrochloride Tablet
NDC Package 24658-720-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Flavoxate Hydrochloride tablets are indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis. This formulation utilizes a tablet delivery system. Marketed by Puracap Laboratories Llc Dba Blu Pharmaceuticals, this product is identified by NDC 24658-720 and is authorized under FDA application ANDA076835.

Identification & Billing

NDC Package Code
24658-720-01
Package Description
100 TABLET in 1 BOTTLE
Product Code
24658-720
11-Digit Billing Format
24658072001
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
100 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Flavoxate Hydrochloride
Non-Proprietary Name
Flavoxate Hydrochloride
Substance Name
Flavoxate Hydrochloride
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
FLAVOXATE HYDROCHLORIDE 100 mg/1
Pharmacologic Class
Usage Information
Flavoxate hydrochloride tablets are indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis. Flavoxate hydrochloride tablets are not indicated for definitive treatment, but are compatible with drugs used for the treatment of urinary tract infections.

Regulatory & Marketing

Labeler Name
Puracap Laboratories Llc Dba Blu Pharmaceuticals
Product Type
Human Prescription Drug
FDA Application #
ANDA076835
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
12-15-2016
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 24658-720-01 identifies a specific commercial package of 100 tablet in 1 bottle of Flavoxate Hydrochloride, a human prescription drug labeled by Puracap Laboratories Llc Dba Blu Pharmaceuticals. This tablet is formulated for oral use and contains flavoxate hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Puracap Laboratories Llc Dba Blu Pharmaceuticals on December 15, 2016. The current certification is valid through December 31, 2026.

How is this Puracap Laboratories Llc Dba Blu Pharmaceuticals product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 24658072001. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
24658-720-01
11-Digit CMS (5-4-2)
24658-0720-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.